Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 12Breast Neoplasms 9Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 5Squamous Cell Carcinoma of Head and Neck 4Endometrial Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasms, Unknown Primary 2Neoplasms 2NSCLC 2Melanoma 2Esophageal Neoplasms 2Adenocarcinoma 2Urologic Neoplasms 1Urogenital Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcopenia 1

Interventions

Paclitaxel 2Carboplatin 2talazoparib 1olaparib 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Metastatic Breast Cancer × CP protocol × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡